Header

Neuroendocrine/Carcinoid Clinical Trials

Category:Adult
Status:Active

Displaying all 5 trials

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 16-072

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigat...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase: 2

Protocol Number: 12-456

A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas

This research study is studying radiation therapy as a possible treatment for meningioma or tumor on the lining of the brain. The study drug or intervention involved in this research study is Inten...

Diagnosis: Neuroendocrine/Carcinoid

Phase: 1 / 2

Protocol Number: 15-542

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocr...

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 16-450

Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of ...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase:

Protocol Number: 16-705

'